Supported by
Our pillars
High-quality biomedical data sets
Targeted and sensitive algorithms
to extract clinically relevant insight, integrated into a proprietary data analytics platform through continuous development and application of most appropriate technology.
Industrialization and adoption
Single-cell data offers unprecedented biological resolution but is overly complex to analyze and interpret. Scailyte develops new data analytics approaches with the aim to extract clinically relevant insights and turn them into applications that will improve patient outcomes and save millions of lives.
We are applying ScaiVision™, our proprietary biomarker discovery platform, to discover novel molecular signatures from single-cell data and develop the next generation of precision diagnostics.
From discovery to next generation clinical applications
Study Design
Wet/Dry lab setup and experimental design
Data analysis workflow
Data Acquisition
Biomedical insights
Diagnostic development
Making groundbreaking discoveries and bringing innovations into clinical practice require collaborations and joint-ventures.
Scailyte provides a unique solution by our discovery platform using single cell technology and artificial intelligence to advance discoveries in life science faster. We are always looking for partners to accelerate this further to address the unmet needs for patients.
Our investors
Recent News
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Recent News
Interview with Scailyte’s CEO Peter Nestorov
In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO
Recent News
Interview with Scailyte Founder Prof. Dr. Manfred Claassen
In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri
Recent News
Scailyte: simplifying difficult diagnoses
Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare
Recent News
Scailyte among The Spinoff Prize finalists
Scailyte is among the ten selected young science-based university spinoff companies that showcase th
Recent News
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Interview with Scailyte’s CEO Peter Nestorov
In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO
Interview with Scailyte Founder Prof. Dr. Manfred Claassen
In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen descri
Recent News
Scailyte: simplifying difficult diagnoses
Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare
Scailyte among The Spinoff Prize finalists
Scailyte is among the ten selected young science-based university spinoff companies that showcase th